Regeneron Pharmaceuticals develops and commercializes biopharmaceutical therapies, and its financial profile is characterized by very strong liquidity and cash generation alongside volatile top‑line and per‑share revenue trends.
Key findings: The company demonstrates strong liquidity and cash flows but faces volatility in revenue per share and net income, with a notable cash‑conversion gap to watch.
Monitoring revenue trends, cash conversion, and margin dynamics will be critical for assessing future performance.
The foundation of business quality and long-term value creation
REGENERON PHARMACEUTICALS, INC.'s revenue series shows pronounced quarter-to-quarter variability with recent large swings. Revenue rose to $3.82B for the quarter ending 2025-12-31 and then declined to $669.4M in the quarter ending 2026-03-31. The history includes other multi‑billion quarters (for example $4.51B in 2018-12-31 and $4.10B in 2015-01-01) as well as several quarters reporting negative revenue (for example -$2.24B in 2025-03-31, -$3.59B in 2017-01-01, and -$957.0M in 2018-07-01).
Net income has also shown large swings but remained positive in recent periods, rising to $2.30B for the quarter ending 2025-12-31 after $1.39B in 2025-06-30 and $808.7M in 2025-03-31. Earlier notable net income peaks include $2.95B (2023-12-31) and $3.10B (2021-06-30). The most recent reported revenue was $669.4M (period ending 2026-03-31). The most recent reported net income was $2.30B (period ending 2025-12-31).
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Over the period Jan 2025 to Dec 2025, Regeneron Pharmaceuticals Inc converts approximately 54¢ of every revenue dollar into gross profit (gross margin: 54.3%).After accounting for operating expenses and taxes and expenses, the company retains 214.4% as net profit margin, resulting in $4.50B in net earnings.
Period Information
Report Type: Annual (10-K)
Period: Jan 2025 to Dec 2025
Analyzing long-term margin stability and competitive positioning
REGENERON PHARMACEUTICALS, INC. shows a clear divergence in the most recent periods: trailing gross margin has declined over the last three reported points from 83.5% (2024-12-31) to 73.1% (2025-03-31) and to 54.3% (2025-12-31), while both operating and net margins expanded sharply in the same window. Operating margin moved from 74.3% (2024-12-31) to 154.1% (2025-03-31) and to 170.3% (2025-12-31); net profit margin rose from 82.2% to 166.8% and then to 214.4% over those quarters. The most recent data therefore show a declining gross margin alongside substantially higher reported operating and net margins.
Looking further back, gross margins were elevated in earlier years (94.1% in 2015, 93.1% in 2018, and 105.6% in 2017) while operating and net margins have been more volatile historically (notably negative operating and net margins in 2017: -57.9% and -33.4%, respectively, then large positive margins by 2018). The most recent values are: Gross Margin 54.3%, Operating Margin 170.3%, Net Profit Margin 214.4%.
Understanding Profit Margins
Between Jan 2025 and Dec 2025, Regeneron Pharmaceuticals Inc converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
REGENERON PHARMACEUTICALS, INC.'s trailing twelve‑month net income rose sharply into 2021, peaking above $8.0B, then declined through 2022 into the $4B range. After bottoming near $3.95B at the end of 2023, net income moved higher through early 2025 (peaking at $5.22B in the 2025‑03‑31 TTM) before falling to $4.50B in the latest 2025‑12‑31 TTM. The primary inflection points are the 2021 peak above $8B and the multi‑quarter decline through 2022, followed by a recovery into early 2025 and a subsequent decline by year‑end 2025.
The most recently reported Net Income (TTM) was $4.50B and the most recently reported Operating Cash Flow (TTM) was $2.62B.
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
Trailing Twelve Months
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
REGENERON PHARMACEUTICALS, INC.'s ROE shows a pronounced peak in 2020–2021, reaching quarterly highs above 50% (51.1% on 2021-06-30 and 49.4% on 2021-09-30) and remaining elevated through 2021 (43.0% on 2021-12-31). Beginning in 2022 there is a clear inflection: ROE fell to 39.8% on 2022-03-31, then declined more sharply to the mid-20s by mid–late‑2022 (27.5% on 2022-06-30, 25.0% on 2022-09-30) and settled into the mid‑teens by the end of 2023 (15.2% on 2023-12-31).
In the most recent quarters ROE has been in the mid‑teens with modest quarter‑to‑quarter movement: 15.0% for period ending 2024-12-31, rising to 17.8% on 2025-03-31 and 17.3% on 2025-06-30, then declining to 14.4% for the latest quarter. The most recent ROE for REGENERON PHARMACEUTICALS, INC. was 14.4% (period ending 2025-12-31).
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
REGENERON PHARMACEUTICALS, INC.'s trailing twelve-month operating cash flow in the available series rose from $1.33B in 2015 to $2.62B by the 2020 TTM, representing the strongest positive cash source shown.
Investing cash flow has been consistently negative across the history provided, with the most recent TTM (2025-12-31) at -$629.1M.
Financing cash flow shifted from positive inflows in 2010—2011 to sustained outflows in later years, with large negative TTM amounts in 2020 and 2021 and a less negative TTM in 2022.
The most recent trailing twelve-month values are: Operating Cash Flow (TTM) $2.62B; Investing Cash Flow (TTM) -$629.1M (2025-12-31); Financing Cash Flow (TTM) -$1.01B (2022-12-31).
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Trailing Twelve Months
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
REGENERON PHARMACEUTICALS, INC.'s trailing twelve-month P/E has fluctuated recently, falling from 26.5x at 2023-12-31 to 18.7x at 2024-12-31, then declining further to 14.1x on 2025-03-31 and reaching a trough of 11.7x on 2025-06-30. In the second half of 2025 the P/E reversed direction and rose to 19.9x by 2025-12-31, marking a clear inflection between mid-2025 and year-end 2025.
Over the longer history shown, the P/E reached very high levels in 2014–2016 (peaking above 130x in 2014-12-31 and remaining elevated through 2016), then trended lower into 2021 when it was in the single digits (8.2x–9.1x across 2021 quarters) before recovering into 2023. The most recent Price-to-Earnings ratio was 19.9x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.